Lakefront Biotherapeutics (GXEA) Price & Analysis

0 Followers

GXEA Stock Chart & Stats

€24.60

-€0.60(-2.38%)

At close: Jul 24 4:00 PM EDT

€24.60

-€0.60(-2.38%)

Day’s Range― - ―

52-Week Range€22.40 - €31.40

Previous CloseN/A

Volume0.00

Average Volume (3M)22.00

Market Cap

€1.67B

Enterprise Value-€451.30

Total Cash (Recent Filing)€2.24B

Total Debt (Recent Filing)€6.36M

Price to Earnings (P/E)2.8

Beta0.26

Next Earnings

Nov 12, 2026

EPS Estimate

-0.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)9.05

Shares Outstanding65,897,070

10 Day Avg. Volume35

30 Day Avg. Volume22

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)0.57

Price to Sales (P/S)1.65

P/FCF Ratio-6.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€22.29

Price Target Upside-9.38% Downside

Rating ConsensusHold

Number of Analyst Covering2

EPS Forecast (FY)-2.99

Revenue Forecast (FY)€29.72M

Bulls Say, Bears Say

Bulls Say

Strategic Ouro/Gilead PartnershipThe transaction transforms Lakefront into an immunology-focused company with a lead clinical asset, additional pipeline programs, Gilead development support, and royalty economics that could provide durable strategic value.

Strong Balance Sheet And LiquidityVery low leverage and substantial remaining liquidity give Lakefront flexibility to fund gamgertamig, pursue strategic transactions, absorb development risk, and maintain operations without near-term dependence on debt markets.

Regulatory Support For GamgertamigAdditional FDA orphan designation broadens the asset’s regulatory positioning and potential indications. Combined with active trials and planned expansion, it may support a more focused, capital-efficient path toward development.

Bears Say

Large Planned Cash OutflowsThe Ouro acquisition and portfolio wind-down require substantial near-term cash deployment. Although liquidity remains strong, these commitments reduce financial flexibility and increase execution risk if development spending or restructuring costs rise.

Persistent Operating Cash BurnContinued cash consumption despite reported profitability indicates earnings are not yet supported by recurring operating cash generation. Sustained R&D and restructuring needs could gradually erode the balance sheet before products reach approval.

Clinical And Competitive Execution RiskGamgertamig’s early data are encouraging but not conclusive. Registrational studies must validate efficacy and safety in a competitive field, and setbacks in dosing, durability, or regulation could materially limit the pipeline’s long-term value.

Lakefront Biotherapeutics News

Lakefront Biotherapeutics granted orphan drug designation for gamgertamig

Lakefront Biotherapeutic (LKFT) announced that the FDA has granted orphan drug designation to gamgertamig for the treatment of...

4d ago

GILD

LKFT

Lakefront Biotherapeutics price target lowered to $26 from $30 at Morgan Stanley

Morgan Stanley analyst Judah Frommer lowered the firm’s price target on Lakefront Biotherapeutics (LKFT) to $26 from $30...

17d ago

LKFT

Lakefront Biotherapeutics Buys Back 104K Shares in August Repurchase Tranche

An announcement from Lakefront Biotherapeutics ( ($LKFT) ) is now available. Between August 3 and August 7, 2026,...

16d ago

LKFT

Lakefront Biotherapeutics Posts First-Half 2026 Results, Closes Ouro Deal and Reaffirms €2B Cash Guidance

Lakefront Biotherapeutics ( ($LKFT) ) just unveiled an update. On August 10, 2026, Lakefront Biotherapeutics reported unaudited first-half...

16d ago

LKFT

Is LKFT a Buy, Before Earnings?

Lakefront Biotherapeutics (LKFT) is scheduled to report 2nd quarter earnings on 08/10/2026. Regarding Q2 estimates, Wall Street analysts...

20d ago

LKFT

Lakefront Biotherapeutics Buys Back 98,648 Shares Under Ongoing Repurchase Program

The latest announcement is out from Lakefront Biotherapeutics ( ($LKFT) ). On July 21, 2026, Lakefront Biotherapeutics reported...

1M ago

LKFT

Lakefront Biotherapeutics Board Member Resigns After Sanofi R&D Appointment

Lakefront Biotherapeutics ( ($LKFT) ) has provided an update. Lakefront Biotherapeutics, a Belgium-based biotechnology company listed on Euronext...

2M ago

LKFT

Lakefront Biotherapeutics resumed with an Equal Weight at Morgan Stanley

Morgan Stanley resumed coverage of Lakefront Biotherapeutics (LKFT) with an Equal Weight rating and $30 price target after...

2M ago

GILD

LKFT

Judah Frommer Maintains Hold on LKFT, Citing Early but Strategic Gamgertamig Acquisition and Limited Economic Upside

Morgan Stanley analyst Judah Frommer maintained a Hold rating on Lakefront Biotherapeutics today and set a price target...

2M ago

LKFT

Lakefront Biotherapeutics Buys Back Over 104,000 Shares Under June 2026 Repurchase Program

Lakefront Biotherapeutics ( ($LKFT) ) has provided an update. Between June 29 and July 3, 2026, Lakefront Biotherapeutics...

2M ago

LKFT

Lakefront Biotherapeutics Details June Share Buybacks Under Ongoing Repurchase Program

Lakefront Biotherapeutics ( ($LKFT) ) has shared an announcement. Between June 22 and June 26, 2026, Lakefront Biotherapeutics...

2M ago

LKFT

Lakefront Biotherapeutics Discloses New 5% Stake by Madison Avenue Partners

Lakefront Biotherapeutics ( ($LKFT) ) has issued an update. On June 29, 2026, Lakefront Biotherapeutics reported that it...

2M ago

LKFT

Lakefront Biotherapeutics Buys Back 77,667 Shares Under June 2026 Repurchase Program

Lakefront Biotherapeutics ( ($LKFT) ) just unveiled an announcement. Between June 15 and June 19, 2026, Lakefront Biotherapeutics...

2M ago

LKFT

Lakefront Biotherapeutics announces EUR 50M share repurchase program

Lakefront Biotherapeutics (LKFT) announced the launch of a share repurchase program, under which the company may repurchase ordinary...

3M ago

LKFT

GXEA FAQ

What was Lakefront Biotherapeutics’s price range in the past 12 months?

Lakefront Biotherapeutics lowest stock price was €22.40 and its highest was €31.40 in the past 12 months.

What is Lakefront Biotherapeutics’s market cap?

Lakefront Biotherapeutics’s market cap is €1.67B.

When is Lakefront Biotherapeutics’s upcoming earnings report date?

Lakefront Biotherapeutics’s upcoming earnings report date is Nov 12, 2026 which is in 76 days.

How were Lakefront Biotherapeutics’s earnings last quarter?

Lakefront Biotherapeutics released its earnings results on Aug 10, 2026. The company reported €0.029 earnings per share for the quarter, beating the consensus estimate of -€0.125 by €0.154.

Is Lakefront Biotherapeutics overvalued?

According to Wall Street analysts Lakefront Biotherapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lakefront Biotherapeutics pay dividends?

Lakefront Biotherapeutics does not currently pay dividends.

What is Lakefront Biotherapeutics’s EPS estimate?

Lakefront Biotherapeutics’s EPS estimate is -0.7.

How many shares outstanding does Lakefront Biotherapeutics have?

Lakefront Biotherapeutics has 65,897,070 shares outstanding.

What happened to Lakefront Biotherapeutics’s price movement after its last earnings report?

Lakefront Biotherapeutics reported an EPS of €0.029 in its last earnings report, beating expectations of -€0.125. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Lakefront Biotherapeutics?

Currently, no hedge funds are holding shares in DE:GXEA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Lakefront Biotherapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-14.52%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Lakefront Biotherapeutics

Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.

Lakefront Biotherapeutics (GXEA) Earnings & Revenues

Historic Earnings Reports

GXEA Company Deck

GXEA Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call highlights a major strategic transformation with a high‑profile Ouro/Gilead transaction that brings a promising clinical asset (gamgertamig) and unlocks substantial financial flexibility. Operationally, the company reported meaningful quarterly improvement in operating loss and a net profit driven by financial gains, maintained a strong cash position, and emphasized cost discipline and capital‑efficient development plans. Offsetting these positives are a very large near‑term cash deployment (upfront and wind‑down costs), a steep YoY revenue decline driven by prior‑year accounting recognition, continued operating losses, and clinical and competitive risks inherent to the BCMA/CD3 space. On balance, the strategic upside and improved reported results outweigh the near‑term financial outflows and risks.View all DE:GXEA earnings summaries

GXEA Stock 12 Month Forecast

Average Price Target

€22.29

▼(-9.38% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"€21","30":"€30","23.25":"€23.3","25.5":"€25.5","27.75":"€27.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.29163118,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€22.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.29163118,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€22.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.29163118,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€22.29</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,23.25,25.5,27.75,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24,23.868587013846152,23.73717402769231,23.60576104153846,23.474348055384617,23.34293506923077,23.21152208307692,23.080109096923078,22.94869611076923,22.817283124615383,22.68587013846154,22.55445715230769,22.423044166153847,{"y":22.29163118,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24,23.868587013846152,23.73717402769231,23.60576104153846,23.474348055384617,23.34293506923077,23.21152208307692,23.080109096923078,22.94869611076923,22.817283124615383,22.68587013846154,22.55445715230769,22.423044166153847,{"y":22.29163118,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24,23.868587013846152,23.73717402769231,23.60576104153846,23.474348055384617,23.34293506923077,23.21152208307692,23.080109096923078,22.94869611076923,22.817283124615383,22.68587013846154,22.55445715230769,22.423044166153847,{"y":22.29163118,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.4,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.6,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29.2,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.8,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.8,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":28.2,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.8,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":23.8,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.4,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26.2,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":24,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >